Tyrosine kinase inhibitors and the thyroid.
Tyrosine kinase inhibitors and the thyroid.
Best Pract Res Clin Endocrinol Metab. 2009 Dec;23(6):713-722
Authors: Sherman SI
Protein tyrosine kinase inhibitors (TKIs) have emerged as significant targets for novel cancer therapies. For patients with differentiated or medullary carcinomas unresponsive to conventional treatments, multiple novel therapies primarily targeting angiogenesis have entered clinical trials. Partial response rates up to 30% have been reported in single-agent studies, but prolonged disease stabilisation is more commonly seen. The most successful agents target the vascular endothelial growth factor receptors. Sorafenib and sunitinib have had promising preliminary results reported and are being used selectively for patients who do not qualify for clinical trials. Treatment for patients with metastatic or advanced thyroid carcinoma now emphasises clinical trial opportunities for novel agents with considerable promise. Adverse effects on thyroid function and thyroid hormone metabolism have also been seen with several TKIs, necessitating prospective thyroid function testing for all patients starting therapy.
PMID: 19942148 [PubMed - as supplied by publisher]
Sponsored Content:
This entry was posted on Saturday, November 28th, 2009 at 6:21 am and is filed under Best Pract Res Clin Endocrinol Metab. You can follow any responses to this entry through the RSS 2.0 feed. You can skip to the end and leave a response. Pinging is currently not allowed.
